Anthem Biosciences Share Price Highlights: Strong Listing at ₹731.65, Up 28.36% from IPO Price

Anthem Biosciences made a powerful debut on the Indian stock market on July 21, 2025, impressing investors with a listing that exceeded expectations. The stock ended the day at ₹731.65 per share on the NSE, registering a 28.36% premium over its Initial Public Offering (IPO) price of ₹570. This strong listing not only rewarded IPO investors handsomely but also demonstrated the market’s confidence in the company’s long-term growth story.

IPO Overview: A Massive Success

Anthem Biosciences’ IPO opened for subscription from July 14 to July 16, with a price band of ₹540 to ₹570 per share. The IPO attracted strong interest across investor categories, leading to an overall subscription of 63.86 times.

• Qualified Institutional Buyers (QIBs): 192.8 times

• Non-Institutional Investors (NIIs): 44.7 times

• Retail Individual Investors (RIIs): 5.98 times

This overwhelming demand reflected investors' positive sentiment toward the company's fundamentals, financial performance, and growth prospects in the biotech space.

Listing Day Highlights

On its listing day, Anthem Biosciences shares opened at ₹723.05 on the NSE and ₹723.10 on the BSE, already delivering nearly a 27% gain over the issue price. As trading continued, the stock maintained upward momentum and finally closed at ₹731.65 on the NSE and ₹730.35 on the BSE — a strong 28.36% return for investors who were allotted shares in the IPO.

This debut made Anthem one of the top-performing IPOs of the year so far, especially within the biotech and healthcare segments.

About the Company

Anthem Biosciences is a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in Bengaluru. It offers end-to-end services to global pharmaceutical, biotech, and nutraceutical companies. The company specializes in:

• Biotech-based Active Pharmaceutical Ingredients (APIs)

• Synthetic and fermentation-based production

• Probiotics, enzymes, and specialty ingredients

• GLP-1 peptide manufacturing

• Biosimilars and high-value complex molecules

Anthem has built a reputation for innovation, quality, and compliance, serving major pharmaceutical clients across the globe.

Why Investors Are Bullish

Several factors contributed to the stock's strong debut:

1. Strong financials: Consistent revenue growth and solid margins in recent years.

2. Favorable industry outlook: Growing global demand for outsourced drug development.

3. High R&D investment: A focus on innovation gives it an edge in the biotech field.

4. Global footprint: Established relationships with top-tier international pharma companies.

What’s Next for Investors?

While the initial pop has brought immediate gains for IPO investors, analysts recommend a cautious approach for those looking to enter post-listing. The stock could see some consolidation or volatility in the short term.

However, long-term investors who believe in the biotech sector’s growth potential may find Anthem Biosciences to be a promising candidate for their portfolio — especially if it continues to scale and expand its global partnerships.

Conclusion

Anthem Biosciences has made a stellar stock market debut, closing at ₹731.65 — a 28.36% gain over its IPO price. The company’s robust fundamentals, strong investor demand, and strategic global position signal a bright future. As the company begins its journey as a listed entity, all eyes will be on its execution and growth trajectory in the competitive biotech landscape.